Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Non Operating Income came in at $6.4 million in Q1 2026, up 156.73% YoY from $2.5 million in Q1 2025, and up 2657.33% on a QoQ basis from $232000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Non Operating Income data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Non Operating Income rose 156.73% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (up 1774.22% YoY) and the FY2025 annual result came in at $3.2 million, down 77.23% from the prior year.
- Non Operating Income grew to $6.4 million in Q1 2026, from $232000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $10.0 million in Q3 2025 to a low of -$11.3 million in Q1 2025.
- A 5-year average of $2.8 million and a median of $3.5 million in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 226800.0% — and 2025, when it slumped 369.27%.
- Tracing RXRX's Non Operating Income over 5 years: stood at $3.5 million in 2022, then sank by 46.36% to $1.9 million in 2023, then surged by 160.1% to $4.9 million in 2024, then tumbled by 95.24% to $232000.0 in 2025, then surged by 2657.33% to $6.4 million in 2026.
- The last three Non Operating Income figures came in at $6.4 million (Q1 2026), $232000.0 (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.96 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 232,000.00 |
| Sep 30, 2025 | 9.95 Mn |
| Jun 30, 2025 | 4.33 Mn |
| Mar 31, 2025 | -11.28 Mn |
| Dec 31, 2024 | 4.87 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 2.48 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 6.53 Mn |
| Jun 30, 2023 | 4.99 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 3.49 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 631,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | -1.03 Mn |